



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Date: March 24, 2006

To: Primary Clinical Research Associates

From: Lori K. Bratvold
Protocol Development Coordinator

Re: N0572: A Phase I/II trial of Sorafenib and CCI-779 in recurrent malignant astrocytoma.

The above study is now active.

A protocol and forms packet are enclosed. You may submit this protocol to your IRB for approval.

Please note that this study was approved by the National Cancer Institute on *February 27, 2006*.

If you have any questions, please feel free to contact me.

Enclosure